Long-term Neutralizing Antibody Levels Against Measles and Rubella Viruses Among Adults With 3 Doses of Measles-Mumps-Rubella Vaccine

Oluwakemi D Alonge,Mona Marin,Carole J Hickman,Sun B Sowers,Min-hsin Chen,Lijuan Hao,Sara Mercader,Elina El-Badry,David L McClure,Joseph P Icenogle,David E Sugerman,Stephen N Crooke,Huong Q Nguyen

DOI: https://doi.org/10.1093/ofid/ofad700

2024-01-01

Open Forum Infectious Diseases

Abstract:Abstract Background A third dose of measles-mumps-rubella vaccine (MMR) may be administered for various reasons, but data on long-term immunity are limited. We assessed neutralizing antibody levels against measles and rubella among adults up to 11 years after receipt of a third MMR dose. Methods In this longitudinal study, healthy adults who received a third MMR dose as young adults (ages 18–28 years) were recalled around 5 years and 9–11 years after the third dose. Measles and rubella antibody levels were assessed by plaque-reduction and immunocolorimetric neutralization assays, respectively. Antibody concentrations <120 mIU/mL and <10 U/mL were considered potentially susceptible to measles and rubella, respectively. Geometric mean concentrations (GMCs) and 95% confidence intervals (CIs) over time were estimated from generalized estimating equation models. Results Approximately 5 and 9–11 years after receipt of the third dose, 405 and 304 adults were assessed, respectively. Measles GMC was 428 mIU/mL (95% CI, 392–468 mIU/mL) 5 years postvaccination, declining to 381 mIU/mL (95% CI, 339–428 mIU/mL) 11 years postvaccination. At the last follow-up visit (9–11 years postvaccination), 10% of participants were potentially susceptible to measles infection. Rubella GMCs were stable throughout the follow-up period (63 U/mL to 65 U/mL); none of the participants was susceptible to rubella at the last follow-up visit. Conclusions Eleven years after receiving a third MMR dose, measles and rubella neutralizing antibody levels remained high in adults. However, on the basis of waning antibody levels, some adults may become susceptible to measles infection over time despite receipt of 3 vaccine doses.

immunology,infectious diseases,microbiology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to evaluate the long - term neutralizing antibody levels in adults up to 11 years after the administration of the third dose of the measles - mumps - rubella (MMR) vaccine, especially the immune responses against the measles and rubella viruses. Specifically, the study focuses on the following aspects:

1. **Evaluating long - term immune responses**: The study aims to understand the long - term immunological effects of the third dose of the MMR vaccine on adults. In particular, whether the neutralizing antibody levels against measles and rubella still remain at the protective level 5 years and 9 - 11 years after vaccination.

2. **Exploring the trend of antibody level changes**: Through longitudinal studies, monitor the changes in antibody levels of participants at different time points to understand the attenuation of antibody levels over time.

3. **Identifying potentially susceptible populations**: The study also attempts to determine which individuals may become susceptible to measles or rubella infection due to a decline in antibody levels over a long period after the third dose of the MMR vaccine.

### Research background

Measles and rubella are highly contagious viral diseases that can cause serious health problems and even death. Although two doses of the MMR vaccine are routinely recommended for children to prevent these diseases, there have been multiple outbreaks of measles and rubella in the United States and other regions in recent years. To improve the protection effect in populations with high vaccine coverage, since 2018, it has been recommended to administer a third dose of the MMR vaccine in certain situations (such as during mumps outbreaks). However, data on the long - term immunological effects of the third dose of the MMR vaccine are very limited.

### Research methods

- **Research design and population**: The study initially recruited 665 healthy adults aged 18 - 28 years. They received the third dose of the MMR vaccine between 2009 - 2010 and were followed up approximately 5 years and 9 - 11 years later.
- **Laboratory methods**: The neutralizing antibody levels against measles and rubella were detected by plaque - reduction neutralization test (PRNT) and immunocolorimetric neutralization test respectively.
- **Statistical analysis**: Generalized estimating equation (GEE) models were used to estimate the geometric mean concentration (GMC) at different time points and their 95% confidence intervals (CI).

### Main results

- **Measles neutralizing antibody**: 5 years and 11 years after the third dose of the MMR vaccine, the GMCs for measles were 428 mIU/mL (95% CI, 392 - 468 mIU/mL) and 381 mIU/mL (95% CI, 339 - 428 mIU/mL) respectively. 10% of the participants were considered potentially susceptible to measles infection at the last follow - up (9 - 11 years later).
- **Rubella neutralizing antibody**: The GMC for rubella remained stable throughout the follow - up period, being 64 U/mL (95% CI, 60 - 68 U/mL), 63 U/mL (95% CI, 59 - 66 U/mL) and 65 U/mL (95% CI, 60 - 71 U/mL) respectively. At the last follow - up, no participants were considered susceptible to rubella infection.

### Conclusions

- **Measles antibody levels**: Although the measles neutralizing antibody levels are still relatively high within 11 years after the third dose of the MMR vaccine, over time, some adults may become susceptible to measles infection due to a decline in antibody levels.
- **Rubella antibody levels**: The rubella neutralizing antibody levels remain stable within 11 years, indicating that the long - term protection effect of the third dose of the MMR vaccine against rubella is good.

### Significance

This study provides important data on the long - term immunological effects of the third dose of the MMR vaccine in adults, which helps to better understand the durability of the vaccine and potentially susceptible populations, thereby providing a scientific basis for public health policies.